Breakfast and Industry Symposium presented by Histosonics

Intermediate Stage HCC Debate (200)

Moderators: Robert Lewandowski, MD, FSIR; Northwestern Medicine; Nishita Kothary, MD, Stanford School of Medicine; Michael C. Soulen, MD, FSIR, FCIRSE, University of Pennsylvania; Marina Baretti, MD, Johns Hopkins School of Medicine

• HCC within UCSF Criteria: TACE Remains the Optimal Strategy for Downstaging, Christos Georgiades, MD, PhD, Johns Hopkins University
• HCC within UCSF Criteria: Y90 has Replaced TACE as Optimal Downstaging Strategy, Irene Bargellini, MD, Candiolo Cancer Institute and University of Turin
• HCC within UCSF Criteria: TACE vs Y90 Discussion, All listed faculty
• Advanced Multifocal HCC: Combination of TACE and Systemic Therapy is Superior to Y90 Combined with Systemic Therapy, Michael C. Soulen, MD, FSIR, FCIRSE, University of Pennsylvania
• Advanced Multifocal HCC: Combination of Y90 and Systemic Therapy is Superior to TACE Combined with Systemic Therapy, Evan Lehrman, MD, FSIR, California Pacific Medical Center
• Advanced Multifocal HCC: TACE or Y90 with Systemic Therapy Discussion, All listed faculty

Lymphatics (200)

Moderators: Max Itkin, MD, University of Pennsylvania; Robert Liddell, MD, Johns Hopkins School of Medicine

• Thoracic Duct Interventions, Max Itkin, MD, University of Pennsylvania
• Pelvic Lymph Leak, Robert Liddell, MD, Johns Hopkins School of Medicine
• Liver Lymphangiography, Protien-losing Enteropathy, and Chylous Ascites, Gregory Nadolski, MD, University of Pennsylvania
• Malignancy and Lower Extremity Swelling, K. Pallav Kolli, MD, University of California San Francisco

Biomarkers for Treatment Response (300)

Moderators: Terence P. Gade, MD, PhD, University of Pennsylvania; Mishal Mendiratta-Lala, MD, University of Michigan

• Imaging Biomarkers of Treatment Response in HCC, Mishal Mendiratta-Lala, MD, University of Michigan
• Neuroendocrine Tumors, Erica Alexander, MD, Memorial Sloan Kettering Cancer Center
• HCC, Terence P. Gade, MD, PhD, University of Pennsylvania
• Cholangiocarcinoma, Christina Mosconi, MD, IRCCS, Policlinico di Sant'orsola Bologna
• ctDNA for GI Malignancies, Adam Burgoyne, MD, PhD, University of California San Diego

Discovery Theatre Programming

• Building IO in Private Practice: How I Did It (All levels)
  • Moderators: Jonathan Steinberger, MD, Cedars Sinai Medical Center; Charles Nutting, DO, FSIR, Image Guided Therapy

Scientific Oral Abstracts (200)

Moderators: Isabel Gala Newton, MD, PhD, VASDMC and UCSD; Nadine Abi-Jaoudeh, MD, University of California Irvine

• Hepatic Deformable Image Registration Prediction with 3-Dimensional Neural Network to Reduce Ablation Image Processing Time, Xinyue Zhang, MA, The University of Texas MD Anderson Cancer Center; Rice University
• Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET), Michael C. Soulen, MD, Abramson Cancer Center, University of Pennsylvania
• Five-year overall survival and overall survival by tumor response measures from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma, Farshid Dayyani, MD, PhD, University of California Irvine
• Adjuvant Immunotherapy After Transarterial Radioembolization in Patients with High-Risk Hepatocellular carcinoma, Josh G. Kim, BA, Icahn School of Medicine at Mount Sinai
• Percutaneous Cryoablation versus Microwave Ablation for Hepatocellular Carcinoma: Comparative Study of Safety and Oncologic Outcomes, David Dimitrios Chlorogiannis, MD, Department of Radiology, Brigham and Women's Hospital
• Outcomes in patients requiring percutaneous transhepatic biliary drainage post-pancreaticoduodenectomy: a single-center experience, Laurel Chen, MBE, Medical College of Wisconsin
• Association of Neuroendocrine Liver Tumor Burden with Outcomes after Embolization, PRRT and CapTem, Cathal O'Leary, MB, BCh, BAO, University of Toronto

Y90 Dosimetry (200)

Moderators: John D. Louie, MD, Stanford University; Beau Toskich, MD, Mayo Clinic

• Dosimetry Updates: HCC and Cholangiocarcinoma, Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School
• Dosimetry Updates for Metastatic Disease, Nima Kokabi, MD, University of North Carolina Chapel Hill
• Single Session Mapping and Treatment, Edward Kim, MD, Mount Sinai Health Systems
• Navigating Complex Anatomy, John D. Louie, MD, Stanford University

Lunch and Industry Symposium presented by Boston Scientific

Discovery Theatre Programming

• 12:15 - 12:45 p.m. - Young IO Research Fellowship Presentations (All levels)
  • Moderator: Lynn Savic, MD, Universitätsmedizin Charité Berlin
  • Percutaneous Intratumoral Immunoadjuvant Gel to Increase Checkpoint Inhibitor Response in Pancreatic Cancer Liver Metastases, David Dimitrios Chlorogiannis, MD, MSc(c/Res), PhDc, Massachusetts General Hospital, Brigham and Women’s Hospital, Harvard Medical School
  • Exploring the Molecular Signatures of Y-90 Resistance in Hepatocellular Carcinoma: A Translational Approach, Christine Yoon, MS, Albert Einstein College of Medicine
• 12:45 - 1:00 p.m. - Product Theatre presented by Siemens/Varian

Lung Tumor Board (200)

Moderators: Alda Tam, MD, MD Anderson Cancer Center; Florian J. Fintelmann, MD, Massachusetts General Hospital

• Treatment Modality Selection for Ablation of Lung Nodules, Damian E. Dupuy, MD, FACR, Cape Cod Hopsital and Brown University
• Advanced Techniques in Lung Ablation, Robert Suh, MD, David Geffen School of Medicine at UCLA
• Combination of Local and Systemic Therapies, Claire Mulvey, MD, University of California San Francisco
• Treatment of Oligometastatic Disease in Lung Cancer, Erica Alexander, MD, Memorial Sloan Kettering Cancer Center
• Tumor Board, All session faculty listed above; Michael Pritchett, DO, MPH, FirstHealth of the Carolinas and Pinehurst Medical Center

mCRC Tumor Board (200)

Moderator: Constantinos Sofocleous, MD, PhD, FSIR, FCIRSE, Memorial Sloan Kettering Cancer Center; Bela Kis, MD, PhD, FSIR, Moffitt Cancer Center

• Current Concepts in Ablation for Colorectal Liver Metastases: Lessons Learned from Recent Trials, Grant Schmidt, MD, Mayo Clinic
• Combination Therapy: Y90 with Chemotherapy, Suvranu Ganguli, MD, Boston Medical Center/Boston University School of Medicine
• Oligomets in Colon Cancer, Stephen J. Hunt, MD, PhD, FSIR, University of Pennsylvania
• Role of Chemoembolization for mCRC, Thomas Vogl, MD, Clinic for Radiology and Nuclear Medicine
• Tumor Board, All session faculty listed above, Brendan C. Visser, MD, Stanford University; Sidharth Anand, MD, MBA, UCLA

Discovery Theatre Programming

• 2:45 - 3:15 p.m. - Trials and Tribulations: Getting Started in Clincal Research (All levels)
  • Moderator: Khashayar Farsad, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Faculty: Clifford R. Weiss, MD, FSIR, FCIRSE, Johns Hopkins University School of Medicine; Florian J. Fintelmann, MD, Massachusetts General Hospital
• 3:15 - 3:30 p.m. - Product Theatre presented by RenovoRx

Must-Know Papers (100)

Moderators: Rony Avritshcer, MD, MD Anderson Cancer Center; Terence P. Gade, MD, PhD, University of Pennsylvania

• IMbrave/150/Himalaya Trilas, Joseph Erinjeri, MD, PhD, Memorial Sloan Kettering Cancer Center
• Intraprocedural versus initial follow-up ablative marigin assessment after mCRC Liver Ablation, Ethan Lin, MD, MD Anderso Cancer Center
• MRI-guided stereotactic ablative body radiotherapy versus CT-guided pancreatic IRE, Florentine Timmer, MD, Amsterdam UMC
• Sublobar resection, Stereotactic Body Radiation Therapy and Percutaneous ablation for lung cancer, Matthew Callstrom, MD, PhD, Mayo Clinic
• Percutaneous MWA versus robot-assisted partial nephrectomy for stage I RCC, Dimitrios Filippiaidis, MD, PhD, MSc, EBIR, National and Kapodistrian University of Athens

Hands-on Y90 Dosimetry Block 1* (200)

*Pre-registration is required to secure a workstation, at no additional fee. Participants will work in pairs to apply contouring principles for practical application. This session will use the MIM software as a primary example. Registrants are strongly encouraged to attend both blocks for a well-rounded educational experience. Additional space will be available for observers based on room capacity.

Moderator: Nima Kokabi, MD, University of North Carolina Chapel Hill

Faculty: Juan Martin Gimenez, MD, Ochsner Health; Tyler Sandow, MD, Ochsner Health; David S. Wang, MD, FSIR, Stanford Medicine; Ammar Sarwar, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School; Beau Toskich, MD, Mayo Clinic; Venkatesh (Kavi) Krishnasamy, MD, FCIRSE, UAB

Ablation vs. Radiation Debate: SIO Meets ASTRO (200)

Moderators: Muneeb Ahmed, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School; David Breen, MD, FRCR, University Hospitals Southampton; Jack Jennings, MD, PhD, FACR, FSIR, FCIRSE, Washington University

• Liver, Riad Salem, MD, MBA, Northwestern and Mekhail Anwar, MD, PhD, UC San Francisco and UC Berkeley
• Renal Cancer, Thomas Atwell, MD, FSIR, Mayo Clinic and Chad Tang, MD, MD Anderson Cancer Center
• Spinal Palliative, Jason R. Levy, MD, FSIR, Northside Hospital and James Urbanic, MD, University of California San Diego

Breakfast and CME Session: Optimal Preparation and Treatment Endpoints in cTACE (200)

Breakfast will be provided. Following the overview, participants will engage in hands-on learning at workstations supervised by expert faculty

• Overview, Michael C. Soulen, MD, FSIR, FCIRSE, University of Pennsylvania

Faculty: Nicholas Fidelman, MD, University of California San Francisco; Irene Bargellini, MD, Candiolo Cancer Institute and University of Turin; Nishita Kothary, MD, Stanford School of Medicine; Juan Martin Gimenez, MD, Ochsner Health; William Rilling, MD, FSIR, Medical College of Wisconsin; Tyler Sandow, MD, Ochsner Health; Vijay Ramalingam, MD, FSIR, Beth Israel Deaconess Medical Center/Harvard Medical School; Nadine Abi-Jaoudeh, MD, University of California Irvine; Gregory Nadolksi, MD, University of Pennsylvania; Robert Lewandowski, MD, FSIR, Northwestern Medicine; Daniel Sze, MD, PhD, Stanford Univeristy; Resmi Charalel, MD, MPH, Weill Cornell Medicine

IO Essentials: Sponsored Content presented by AstraZeneca (100)

BCLC C HCC Debate "Who's on First?" (200)

Moderators: Riad Salem, MD, MBA, Northwestern; Roberto Iezzi, MD, FCIRSE, Policlinico A Gemelli - IRCCS - Università Cattolica

• Lobar or Sublobar Portal Vein Invasion, Gregory Nadolksi, MD, University of Pennsylvania and Amit Singal, MD, UT Southwestern Medical Center
• Bilobar or Main Portal Vein Invasion, Daniel Sze, MD, PhD, Stanford University and Marina Baretti, MD, Johns Hopkins School of Medicine
• Patients with Vascular Invasion and Regional Metastases, Guy Johnson, MD, PharmD, University of Washington and Richard S. Finn, MD, Geffen School of Medicine at UCLA

Robotics, Navigation, Guidance, and Confirmation (200)

Moderators: Bruno C. Odisio, MD, PhD, FSIR, MD Anderson Cancer Center; Nadine Abi-Jaoudeh, MD, University of California Irvine

• Augmented Reality, Terence P. Gade, MD, PhD, University of Pennsylvania
• Technical Principles of Navigation, Iwan Paolucci, PhD, D Anderson Cancer Center
• Procedure Planning and Guidance, Nadine Abi-Jaoudeh, MD, University of California Irvine
• Robotics, Luigi A.Solbiati, MD, Humanitas University and Research Hospital
• Confirmation, Bruno C. Odisio, MD, PhD, FSIR, MD Anderson Cancer Center

Discovery Theatre Programming

• Internet: Friend or Foe? (All levels)
  • Moderator: Julius Chapiro, MD, PhD, Yale University School of Medicine 
  • Faculty: Dianne Keen, FRMBA, AbbaDox; Nadine Abi-Jaoudeh, MD, University of California Irvine

Scientific Oral Abstracts (200)

Moderators: Isabel Gala Newton, MD, PhD, VASDMC and UCSD;  Brad J. Wood, MD, NIH NCI NIBIB

• The Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma, Richard S. Finn, MD, Geffen School of Medicine at UCLA
• Safety and treatment response of Pulsed electric field (PEF) ablation therapy for Recurrent Malignant Pleural Mesothelioma (MPM), Shahed Tappuni, MD, University of California Los Angeles
• Safety of CT-guided pulsed electrical field ablation adjacent to sensitive intrathoracic structures for treatment of intrathoracic malignancies, Robert Ryan Meyerhoff, MD,PhD, Duke University
• MR-Guided Cryoablation of Seminal Vesicles: A 10-Year Experience, Ali Ganjizadeh, MD, Mayo Clinic Rochester
• MR-guided Cryoablation in the Treatment of Recurrent Prostate Cancer in the Prostate Bed: An 11-Year Prospective Study, Setayesh Sotoudehnia Korani, SS, Mayo Clinic Rochester
• Outcomes of thermoprotective techniques in image-guided ablation of musculoskeletal tumors, Carl Stokes, MD, Mallinckrodt Institute of Radiology- Washington University School of Medicine in St. Louis
• Irreversible Electroporation in the Canine Spine: Impact on Implanted Tumors and Adjacent Structures, Koustav Pal, MBBS, Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center

Y90 Clinical Applications (200)

Moderators: Charles Y. Kim, MD, Duke University; Robert Lewandowski, MD, FSIR; Northwestern Medicine

• Strategies for Diffuse Bilobar Disease, Charles Y. Kim, MD, Duke University
• Approach to Challenging Patients, Thomas Helmberger, MD, PhD, Munich Klinik Bogenhausen
• Extra-hepatic Applications, Robert Lewandowski, MD, FSIR; Northwestern Medicine
• Holmium-166 and the RALLY Study, Marnix Lam, MD, PhD, University Medical Center Utrecht

Exhibit Hall Open

Lunch and Industry Symposium presented by Varian, a Siemens Healthineers Company

• Bone Tumor Ablation feat. Stryker OptaBlate and Vertebral Augmentation feat. Stryker SpineJack, Jason R. Levy, MD, FSIR, Northside Hospital

Discovery Theatre Programming

• 12:15 - 12:45 p.m. - Industry Abstract Presentations (All levels)
  • Moderator: Isabel Gala Newton, MD, PhD, VASDMC and UCSD
  • Primary efficacy, safety, survival and initial biomarker data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab, Gino K. In, MD, University of Southern California Norris Comprehensive Cancer Center
  • CryoSYNC Gel: A Novel CT-responsive, Biocompatible Nanogel to Enhance Performance of Cryoablation, William Park, PhD, Theromics Inc.
  • Micro-CT imaging following intra-arterial delivery of a radiopaque silicone polymer using a double-balloon occlusion catheter in pigs: A model to analyze tissue penetration via the trans-arterial micro perfusion (TAMP) technique, Paula Novelli, MD, University of Pittsburgh Medical Center
  • Preliminary Safety and Efficacy Data for Microwave Ablation of Liver Tumors from the Global, Multicenter NEUWAVE™ Observational Liver Ablation (NOLA) Registry, Constantinos Sofocleous, MD, PhD, Memorial Sloan Kettering Cancer Center
• 12:45 - 1:00 p.m. - Product Theatre

Future Liver Remnant (200)

Moderator: Peiman Habibollahi, MD, MD Anderson Cancer Center; Nishita Kothary, MD, Stanford School of Medicine

• Surgical Techniques and Estimation of Functional Liver Reserve, Eric Nakakura, MD, PHD, University of California San Francisco
• PVE: Which Embolic to Choose? Jose Hugo Luz, MD, PhD, SOBRICE, FCIRSE, INCA Brazilian National Cancer Institute
• Total Venous Deprivation, Francesco de Cobelli, MD, San Raffaele Hospital and Salute University
• Radiation Lobectomy: Updates and Trials in Progress, Resmi Charalel, MD, MPH, Weill Cornell Medicine

MSK Tumor Board (200)

Moderators: Afshin Gangi, MD, PhD, University Hospital Strasbourg, King’s College London; Brandon M. Key, MD, Medical College of Wisconsin

• Pathalogic Fractures: IR Approach, Steven Yevich, MD, MPH, MD Anderson Cancer Center
• Pathalogic Fractures: Orthopedic Approach, Melissa Zimel, MD, University of California San Francisco
• Ablation and Vertebral Augmentation: Neuroprotective Techniques, Jack Jennings, MD, PhD, FACR, FSIR, FCIRSE, Washington University
• Electrochemotherapy, Frederic Deschampes, MD, PhD, Gustave Roussy
• Tumor Board, All session faculty listed above, Christian Meyer, MD, PhD, Johns Hopkins Hospital

Robotics, Navigation, Guidance, and Confirmation Hands-on (All levels)

Moderator: Bruno C. Odisio, MD, PhD, FSIR, MD Anderson Cancer Center

Faculty: Iwan Paolucci, PhD, D Anderson Cancer Center; Francois H. Cornelis, MD, PhD, Memorial Sloan Kettering Cancer Center; Keith M. Horton, MD, FSIR, MedStar Health/Georgetown University School of Medicine; Luigi A.Solbiati, MD, Humanitas University and Research Hospital; Stephen J. Hunt, MD, PhD, FSIR, University of Pennsylvania; Brian Park, MD, OHSU; Alex King, MBBS, MRCS, FRCR, University Hospitals Southampton; Sean Merrill Tutton, MD, UCSD Health

Discovery Theatre Programming

• 2:45 - 3:15 p.m. - IO in OBL (All levels)
  • David Sperling, MD, FSIR, Columbia University Irving Medical Center; Scott Genshaft, MD, UCLA; Jayson S. Brower, MD, Inland Imaging
• 3:15 - 3:30 p.m. - Product Theatre

SIO Grants (200)

Moderators: Julius Chapiro, MD, PhD, Yale University School of Medicine; Christopher D. Malone, MD, Mallinckrodt Institute of Radiology, Washington University School of Medicine

• 2023 Grant Update: Spatial proteogenomics for prediction of response in combined radioembolization and immunotherapy of HCC, Elif Öcal, MD, LMU
• 2022 Grant Update: Stoking an Anti-Liver Cancer Immune Response with Cryoablation Plus Intratumoral Immunostimulant, Isabel Gala Newton, MD, PhD, VASDMC and UCSD
• 2022 Grant Update: Engineered Extracellular Vesicles to Modulate Immunotherapy in Liver Cancer, Kiyoyuki Minamiguchi, MD, PhD, Nara Medical University
• 2022 Grant Update: Single Cell Analysis of Combined Thermal Ablation and Immunotherapy of HCC, S. Nahum Goldberg, MD, Beth Israel Deaconess Medical Center/Harvard Medical School
• 2022 Grant Update: Immunobiologic and Metabolic Determinants of Response to Combination Locoregional and Immunotherapy in HCC, David Tischfield, MD, PhD, University of Pennsylvania
• Interactive Debate, All

Melanoma (200)

Moderators: David J. Eschelman, MD, FSIR, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University Hospital; Gloria Hwang, MD, FSIR, Stanford University

• Building a Multidisciplinary Melanoma Program, Robert Adamo, MD, Thomas Jefferson University Hospital
• Relative Advantages of Chemoembolization and Immunoembolization, David J. Eschelman, MD, FSIR, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University Hospital
• Y90 with or without Immunotherapy, Gloria Hwang, MD, FSIR, Stanford University
• Ablative Techniques with or without Immunotherapy, Chenyang Zhan, MD, PhD, Memorial Sloan Kettering Cancer Center
• Delcath, Alexander Villalobos, MD, University of North Carolina Chapel Hill

Hands-on Y90 Dosimetry Block 2* (200)

*Pre-registration is required to secure a workstation, at no additional fee. Participants will work in pairs to apply contouring principles for practical application. This session will use the Simplicit90Y software as a primary example. Registrants are strongly encouraged to attend both blocks for a well-rounded educational experience. Additional space will be available for observers based on room capacity.

Moderator: Juan Martin Gimenez, MD, Ochsner Health;

Faculty: Tyler Sandow, MD, Ochsner Health; David S. Wang, MD, FSIR, Stanford Medicine; Beau Toskich, MD, Mayo Clinic; Diana Dinh, MD, MPH, Beth Israel Deaconess Medical Center; Marnix Lam, MD, PhD, University Medical Center Utrecht; Venkatesh (Kavi) Krishnasamy, MD, FCIRSE, UAB

Oligometastatic Disease Tumor Board (200)

Moderators: Martijn R. Meijerink, MD, PhD, FCIRSE, Amsterdam UMC; Alexios Kelekis, MD, PhD, EBIR, FCIRSE, FSIR, National and Kapodistrian University of Athens; A. Nick Kurup, MD, Mayo Clinic

Panelists: Afshin Gangi, MD, PhD, University Hospital Strasbourg, King’s College London; Terence Friedlander, MD, University of California San Francisco; Mekhail Anwar, MD, PhD, UC San Franscico and UC Berkeley

Sunday Soiree* at Alexxa's Las Vegas
*Attendance requires an additional fee.

Breakfast

Practical IO (All levels)

Moderators: Nicholas Fidelman, MD, University of California San Francisco; Aneesa Majid, MD, MBA, Independent

Case presentations by:

• Vladimir Sheynzon, MD, MBA, Columbia University Irving Medical Center
• Gaby E. Gabriel, MD, FSIR, University of Kentucky
• Gina Landinez, MD, MCVI MCI
• David S. Wang, MD, FSIR, Stanford Medicine
• Scott Genshaft, MD, UCLA
• Rajesh Shah, MD, UCSF
• Eric Wehrenberg-Klee, MD, Massachusetts General Hospital
• Ahmad Parvinian, MD, Mayo Clinic
• James Ronald, MD, PhD, Duke University
• Tony Brown, MD, RIA Endovascular
• Todd Schlachter, MD, Yale School of Medicine
• Jin Woo Choi, MD, PhD, Seoul National University Hospital

Case-based Review: M&M (All levels)

Moderators: Daniel Sze, MD, PhD, Stanford University; Charles Nutting, DO, FSIR, Image Guided Therapy

Case presentations by:

• Jeffrey Weinstein, MD, FSIR, Beth Isreal Deaconess Medical Center/Harvard Medical School
• Matthew J. Scheidt, MD, FSIR, Froedtert and the Medical College of Wisconsin
• Jonathan Kessler, MD, City of Hope
• Ken Zhao, MD, Memorial Sloan Kettering Cancer Center
• Igor Latich, MD, Yale University
• Kirema Garcia-Reyes, MD, Icahn School of Medicine at Mount Sinai
• Alex King, MBBS, MRCS, FRCR, University Hospitals Southampton
• Lambros Tselikas, MD, PhD, Gustave Roussy
• Jonathan Morris, MD, Mayo Clinic
• Juan Carlos Perez Lozada, MD, Yale School of Medicine
• Donna D'Souza, MD, FSIR, University of Minnesota
• Elena Violari, MD, Radiology Partners, Franciscan Alliance Hospitals